Eylea and the Diabetic Macular Edema Market: What Lies Ahead?
Diabetic macular edema (DME) occurs in patients with diabetes as a consequence of diabetic retinopathy and is typically referred to as the leading... In DRG Blog/ December, 2018 What Are the Opportunities and Challenges to Drug Development for Diabetic Retinopathy?
Diabetic retinopathy (DR) occurs as a consequence of diabetes and is the leading cause of visual impairment and blindness among the working-age... In DRG Blog/ December, 2018 Schizophrenia Highlights from the 2018 APA Annual Meeting
The 2018 APA (American Psychiatric Association) Annual Meeting was held from May 5 to May 9, 2018 in New York City. At the meeting, a number of... In DRG Blog/ July, 2018 Notable Late-Phase Developments for Negative Symptoms of Schizophrenia
Minerva Neurosciences’ MIN-101 progresses to Phase III and Allergan remains committed to Vraylar’s approval for negative symptoms in the United... In DRG Blog/ January, 2018 One Key Strategy for Wet AMD Development Progresses, the Other Falters
What opportunities remain for wet AMD? Intravitreally administered vascular endothelial growth factor (VEGF) inhibitors - Regeneron/Bayer/Santen’... In DRG Blog/ December, 2017 Is surpassing the efficacy benchmark set by currently used VEGF inhibitors an uphill task for therapies in development for the treatment of wet AMD?
Anti-vascular endothelial growth factors (VEGF) agents (Lucentis, Eylea, and off-label Avastin) are the current standard of care in the treatment... In DRG Blog/ December, 2016